Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
STAT+
First Opinion
The Readout

Regeneron’s all-important trial & Biogen’s burning questions

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Jan. 24, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for January 24, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

What does generative AI mean for health care? We…
What does generative AI mean for health care? We asked the experts
Tired of ‘dead end’ approach, herpes patients mobilize to…
Tired of ‘dead end’ approach, herpes patients mobilize to demand government action
A secret experiment revealed: In a medical first, doctors…
A secret experiment revealed: In a medical first, doctors treat Parkinson’s with a novel brain cell…
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories